Department of Health and Human Services July 21, 2011 – Federal Register Recent Federal Regulation Documents

Draft Guidance for Industry and Food and Drug Administration Staff; Mobile Medical Applications; Availability
Document Number: 2011-18537
Type: Notice
Date: 2011-07-21
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing the availability of the draft guidance entitled ``Mobile Medical Applications.'' FDA is issuing this draft guidance to inform manufacturers, distributors, and other entities about how the FDA intends to apply its regulatory authorities to select software applications intended for use on mobile platforms (mobile applications or ``mobile apps''). At this time, FDA intends to apply its regulatory requirements solely to a subset of mobile apps that the Agency is calling mobile medical applications (mobile medical apps). This draft guidance is not final nor is it in effect at this time.
Center for Scientific Review; Notice of Closed Meeting
Document Number: 2011-18420
Type: Notice
Date: 2011-07-21
Agency: Department of Health and Human Services, National Institutes of Health
Center for Scientific Review Notice of Closed Meetings
Document Number: 2011-18418
Type: Notice
Date: 2011-07-21
Agency: Department of Health and Human Services, National Institutes of Health
Committee Meeting via Conference Call
Document Number: 2011-18392
Type: Notice
Date: 2011-07-21
Agency: Department of Health and Human Services, Administration for Children and Families
Cardiovascular Devices; Classification of Electrocardiograph Electrodes
Document Number: 2011-18391
Type: Rule
Date: 2011-07-21
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is classifying the electrocardiograph electrode, intended to acquire and transmit the electrical signal at the body surface to a processor that produces an electrocardiogram (ECG) or vectorcardiogram, into class II (special controls). FDA is also exempting this device from the premarket notification requirement.
Guidance for Industry and Food and Drug Administration Staff; Class II Special Controls Guidance Document: Electrocardiograph Electrodes; Availability
Document Number: 2011-18390
Type: Notice
Date: 2011-07-21
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing the availability of the guidance entitled ``Class II Special Controls Guidance Document: Electrocardiograph Electrodes.'' The special controls identify the following risks to health associated with electrocardiograph electrodes: Adverse tissue reaction to the skin- contacting electrode materials and misdiagnosis. The guidance document provides information on how to mitigate these risks and recommends testing and labeling for these devices. This guidance document describes a means by which electrocardiograph electrodes may comply with the requirement of special controls for class II devices.
Standard Operating Procedure for “Notice to Industry” Letters
Document Number: 2011-18387
Type: Notice
Date: 2011-07-21
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing the availability of the standard operating procedure (SOP) for ``Notice to Industry'' Letters. The SOP describes the Center for Devices and Radiological Health's (CDRH) process to clarify and more quickly inform stakeholders when CDRH has changed its expectations relating to, or otherwise has new scientific information that could affect, data submitted as part of an Investigational Device Exemption (IDE) or premarket submission that needs to be disseminated in a timely manner.
Announcement of Expansion Supplement Grant Awards
Document Number: 2011-18377
Type: Notice
Date: 2011-07-21
Agency: Department of Health and Human Services, Administration for Children and Families
The Administration for Children and Families (ACF), Administration for Native Americans (ANA), announces the award of ten expansion supplement awards to Native American Tribes that are currently combating the epidemic of health issues in Native America. Expansion supplement funds will support activities associated with the First Lady's initiative, Let's Move! in Indian Country. Under the program, grantee Tribes have set forth goals and milestones that will benefit Native youth, children, and families. The following projects will be supported by the expansion supplement awards: Native Village of Afognak, Kodiak, AK ($20,000). The project will include Let's Move! activities as part of their summer youth camps. Pueblo of Tesuque, Santa Fe, NM ($20,025). The project will include Let's Move! activities in its existing project of building a comprehensive prevention and early intervention program that is focused on building community member awareness of, and ability to, confront challenges. Riverside-San Bernardino County Indian Health, Inc., Banning, CA ($20,000). The project will include healthy living and healthy lifestyles of the Let's Move! initiative in its already existing project that focuses on providing pre-marital, dating violence and communication education. The project also provides pre-marital education to pregnant and parenting adolescents. Yerington Paiute Tribe, Yerington, NV ($19,034). This project will include Let's Move! activities that support the development of a family/community wellness support system. The system provides prevention, intervention, referral and follow-up services to community members. Cornerstone Ministries, Inc., Crownpoint, NM ($20,001). This project will implement Let's Move! activities in its project to increase the awareness and value of healthy families and will include activities in its training of youth workers to conduct relationship education. Eastern Shawnee Tribe of Oklahoma, Wyandotte, OK ($17,490). This project will include Let's Move! activities in its project to encourage healthy eating and exercise to reduce the rate of diabetes among elderly tribal members. Leech Lake, Cass Lake, MN ($19,999). This project will include Let's Move! activities in its project to increase relevant academic and cultural content for an intensive in-service for teachers. Chickaloon Native Village, Chickaloon, AK ($16,948). This project will include Let's Move! activities in its project that encourages tribal governance and land stewardship of Chickaloon traditional lands by designing and implementing a trails and recreation planning, management, and ecotourism plan. White Earth Band of Chippewa, White Earth, MN ($19,940). This project will include Let's Move! activities in its project to improve child well-being and social stability by providing family support services to disadvantaged parents and their children. The American Indian Child Resource Center, Oakland, CA ($20,000). This project will include Let's Move! activities in its project to providing life skills training that fosters and promotes decision making, critical thinking, and independent living skills among young Native Americans living in urban environments.
Agency Information Collection Activities: Proposed Collection; Comment Request
Document Number: 2011-18371
Type: Notice
Date: 2011-07-21
Agency: Department of Health and Human Services, Substance Abuse and Mental Health Services Administration
Unique Device Identification for Postmarket Surveillance and Enforcement; Public Workshop
Document Number: 2011-18369
Type: Notice
Date: 2011-07-21
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing a public workshop on the adoption, implementation, and use of unique device identifiers (UDIs) in various health-related electronic data systems. The purpose of this workshop is to engage multiple stakeholders to obtain information and comments on issues confronting the effective and efficient incorporation of UDIs into appropriate data sets, to identify barriers and incentives to their adoption and use, and to understand the best solutions and practices to resolve open issues. Dates and Times: The public workshop will be held on September 12, 2011, from 1 to 5 p.m. and on September 13, 2011, from 9 a.m. to 5 p.m. Submit electronic and written comments by October 13, 2011. Location: The public workshop will be held at the Bethesda North Marriott Hotel and Conference Center, 5701 Marinelli Road, Bethesda, MD 20852; 301-822-9200. Contact Person: Jay Crowley, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20903, 301-980-1936, e-mail: jay.crowley@fda.hhs.gov Registration: Registration is free and will be on a first-come, first-served basis. To register for the public workshopwhether attending in person or for the Web castplease visit https:// www.fda.gov/UDI (or go the FDA Medical Devices News & EventsWorkshops & Conferences calendar and select this public workshop from the posted events list). Please provide complete contact information for each attendee, including name, title, affiliation, address, e-mail, and telephone number. For those without Internet access, please contact Jay Crowley (see Contact Person) to register. Registration requests should be received by 5 p.m. on September 5, 2011. Early registration is recommended because seating is limited and, therefore, FDA may limit the number of participants from each organization. If time and space permit, onsite registration on the day of the public workshop will be provided beginning at 11 a.m. Hotel reservations can be made by calling the hotel and requesting the group rate for the ``FDA UDI Public Workshop'' room block. If you need special accommodations due to a disability, please contact Jay Crowley (jay.crowley@fda.hhs.gov) at least 7 days in advance. The meeting will also be Web cast. Persons interested in participating by Web cast must register online by 5 p.m. on September 5, 2011. Web cast participants will be sent connection requirements. More information on the Web cast can be found on our Web site at http:/ /www.fda.gov/UDI. By August 12, 2011, and then as available, FDA will post the workshop agenda and discussion topics, registration information, information about lodging, and other relevant information on the Internet at https://www.fda.gov/UDI. Comments: Regardless of attendance at the public workshop, interested persons may submit either electronic or written comments by October 13, 2011. Submit electronic comments to https:// www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. It is only necessary to send one set of comments. It is no longer necessary to send two copies of mailed comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.